NeuroPace Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
NeuroPace (NASDAQ:NPCE) has been analyzed by 6 analysts, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $11.83, a significant increase from the previous $8.00. Analysts from firms like Leerink Partners, Lake Street, Morgan Stanley, Cantor Fitzgerald, and JP Morgan have provided ratings and adjusted price targets. NeuroPace is a medical device company focusing on epilepsy treatments, with recent revenue growth of 47.23% and a market cap below industry average. The company has a high debt-to-equity ratio of 4.38, and its ROE and ROA are below industry standards.
January 30, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroPace has received varied analyst ratings with an average 12-month price target of $11.83, indicating a bullish sentiment. The company's strong revenue growth is positive, but financial leverage and below-average ROE and ROA may concern investors.
The average price target increase suggests analysts are optimistic about NeuroPace's future performance, which could lead to a positive short-term impact on the stock price. However, the high debt-to-equity ratio and below-average ROE and ROA may temper investor enthusiasm, hence the importance score is not at the maximum. The confidence level is at 75 due to the mixed analyst sentiments and the potential risks associated with the company's financial leverage.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100